National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years. - A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma.
Johns Hopkins University - Recruiting 18 years or older. - Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer.
Southwest Oncology Group - Recruiting N/A or older. - S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities.
assessment of therapy complications; psychosocial assessment and care; quality-of-life assessment
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI).
Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial.
H. Lee Moffitt Cancer Center and Research Institute - Recruiting 16 years or older. - A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma.
MART-1; NY-ESO-1; gp100:209-217(210M); gp100:280-288(288V); Montanide ISA 51 VG; BMS-936558
Pfizer - Recruiting 18 years or older. - A Phase 2b, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.
Pfizer - Recruiting 18 years or older. - A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis.
LEO Pharma - Recruiting 18 years or older. - Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis.
ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older. - Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors.
Instituto Nacional de Cancerologia de Mexico - Recruiting 18 years or older. - Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992.
AIO-Studien-gGmbH - Recruiting 18 years or older. - Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP).
Fred Hutchinson Cancer Research Center - Recruiting 18 years or older. - Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma.
James Graham Brown Cancer Center - Recruiting 18 years or older. - Preemptive Therapy Study of Cetuximab(Erbituxr)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients.
Galderma - Recruiting 2 years to 12 years. - Pharmacokinetics and Pharmacodynamics of Calcitriol 3 Mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis.
Centre Francois Baclesse - Recruiting 18 years to 69 years. - Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy.
Lawson Health Research Institute - Recruiting 18 years to 80 years. - Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy.
National Institute of Oncology, Hungary - Recruiting N/A to 75 years. - Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study.
Insertion of suction drain(s) following mastectomy; Adaptive skin sutures.